Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$3.47
-$0.08(-3.76%)
At close: 4:00 PM EDT
$3.47
-$0.08(-3.76%)
Day’s Range― - ―
52-Week Range$0.91 - $4.20
Previous CloseN/A
Volume163.47K
Average Volume (3M)608.30K
Market Cap
$507.85M
Enterprise Value$71.29M
Total Cash (Recent Filing)$11.31M
Total Debt (Recent Filing)$425.00K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding173,922,420
10 Day Avg. Volume728,014
30 Day Avg. Volume608,304
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.75K
Enterprise Value/Ebitda-5.00
Forecast
1Y Price Target
$10.00Price Target Upside188.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical AdvancementRegulatory alignment on a defined Phase 3 pathway materially advances EB613 toward registration and reduces trial-design uncertainty. If execution remains on track, the program could create a clearer route to commercialization and validate Entera’s oral peptide platform over the next several years.
Strong Financing RunwayThe substantial financing gives Entera resources to fund its lead program through anticipated NDA submission rather than relying immediately on additional capital. A longer runway supports continued development of EB613 and EB612 while improving planning flexibility across the pipeline.
Experienced Clinical And Commercial LeadershipAdding senior executives and directors with experience in clinical development, regulatory strategy, global operations, and commercialization strengthens capabilities needed for a late-stage biotech. This expertise may improve execution as Entera advances EB613 and prepares its broader platform for potential partnering or launch.
Bears Say
No Meaningful Commercial RevenueEntera has not yet demonstrated recurring product revenue, leaving financial performance dependent on partnerships, financing, and research-related income. Until a candidate is approved and commercialized, the company’s ability to fund operations internally remains limited and earnings visibility remains weak.
Persistent Cash Burn And Operating LossesHeavy cash outflows show that Entera cannot currently self-finance its development programs from operations. Continued clinical investment will require substantial external resources, making future funding access important and increasing the financial consequences of delays or unsuccessful development outcomes.
Equity Dilution RiskFunding the pipeline through a large share issuance and warrants expands the equity base and can dilute existing holders. Planned increases to the equity incentive plan and related grants could add further dilution, even though the proceeds materially improve development funding and runway.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $4.20 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $507.85M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 10 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.07.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 173,922,420 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went up 5.923%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (188.18% Upside)
$10.00 (188.18% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.44%
12-Months-Change
Fundamentals
Return on Equity
-147.19%
Trailing 12-Months
Asset Growth
-0.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(188.18% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
0.01% Mutual Funds
0.03% Other Institutional Investors
98.62% Public Companies and
Individual Investors